Skip to main content

Table 1 Echocardiographic analysis (baseline) of Con and p85-KO mouse hearts

From: Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase α in mouse

 

BW (g)

HR (bpm)

EDA (cm2)

ESA (cm2)

PWT (cm)

SWT (cm)

RWT

MPI

FS

LV mass (g)

Con

31.8 ± 1.2

439 ± 9

0.168 ± 0.004

0.088 ± 0.003

0.114 ± 0.003

0.104 ± 0.003

0.60 ± 0.02

0.36 ± 0.03

0.45 ± 0.02

0.126 ± 0.004

KO

28.4 ± 1.0

438 ± 11

0.153 ± 0.004*

0.081 ± 0.004

0.108 ± 0.005

0.087 ± 0.002*

0.54 ± 0.02

0.30 ± 0.02

0.45 ± 0.01

0.105 ± 0.005*

  1. The p85-KO and the Cre controls (12–16 week-old, male) were subjected to echocardiography analysis
  2. BW body weight; HR heart rate; EDA end diastolic area; ESA end systolic area; PWT posterior wall thickness; SWT septal wall thickness; RWT relative wall thickness; MPI myocardial performance index; FS fractioning shortening; LV mass left ventricular mass; Con n = 21; KO n = 15
  3. * p < 0.05 v.s. Con